Sponsor: Grayken Center for Addiction TTA, a program of Boston Medical Center
Description: This training provides an overview of the 3 FDA-approved medications for the treatment of opioid use disorder (OUD): buprenorphine, methadone, and naltrexone.
This training satisfies 1.00 hours of the required 8 hours of training for DEA-registered practitioners.
Intended audience:
Medical professionals with prescriptive authority, nurses and support staff who support them looking to increase provision of care for patients with substance use disorder.
Objectives
Following this training, participants will have the knowledge necessary to:
- Explain the major pharmacologic properties of methadone,buprenorphine, and naltrexone.
- Describe 3 medical or social considerations in medication initiation planning.
- Identify patients at risk for severe opioid withdrawal.
- List at least 2 medications that may be utilized to manage symptoms of opioid withdrawal.
- Recall benefits for treatment with injectable buprenorphine.
For more information and to register click here:
This is an open ended event
- Cost:
- no costs